The Food and Drug Administration (FDA) authorized nivolumab as a first-line therapy for patients with NSCLC whose PD-L1 expression is greater than 1% on the basis of the CheckMate 227 results (6). This evidence concerns the gene CD274 and non-small cell lung carcinoma.